

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
 Etsuko MIYAMOTO et al. : **Mail Stop: PCT**  
 Serial No. 10/579,802 : Attorney Docket No. 2006\_0750A  
 Filed May 18, 2006 :

PROTEIN FORMING COMPLEX WITH c-Jun  
 PROTEIN, NUCLEIC ACID ENCODING THE  
 SAME AND METHOD OF USING THE SAME  
**[Corresponding to PCT/JP2004/017306  
 Filed November 19, 2004]**

**SECOND INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☐ each U.S. Patent and U.S. Patent application publication;
- ☐ each reference previously cited in the international application PCT/\_\_\_\_\_; and/or
- ☐ each reference previously cited in prior parent application Serial No. \_\_\_\_\_.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /MKJ/

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

**and thus no certification and/or fee is required.**

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and**

**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
  - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
  - c. ☒ the concise explanation contained in the specification of the present application at pages 3-5,
  - d. ☒ the concise explanation set forth in the attached English language abstract,
  - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Etsuko MIYAMOTO et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/kes  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
July 27, 2006

Sheet 1 of 2

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: July 27, 2006

ATTY DOCKET NO.  
2006\_0750ASERIAL NO.  
10/579,802APPLICANT  
Etsuko MIYAMOTO et al.FILING DATE  
May 18, 2006

GROUP

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
Abs only	AA	98/16636 A1	04/1998	WO			abstract	
Abs only	AB	02/46395 A1	06/2002	WO			abstract	

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AC	Saegusa, A., "Japan boosts proteomics and cell biology..." <i>Nature</i> , Vol. 401, p.313 (1999).
	AD	Dalton, R. et al., "Can researchers find recipe for proteins and chips?", <i>Nature</i> , Vol. 402, pp. 718-719 (1999).
ABS only	AE	Miyamoto, E. et al., "Analyses of protein-protein interactions and gene networks by <i>in vitro</i> virus method", <i>Series Genome Science of Post-sequencing 3, Proteomics</i> , pp. 136 to 145 (2000). (Partial English Translation.)
ABS only	AF	Miyamoto, E. et al., "Applications of puromycin for evolutionary molecular engineering of proteins and analysis of gene networks", <i>Protein, Nucleic Acid and Enzyme</i> , Vol. 46, No. 2, pp. 138 to 147 (2001). (Partial English Translation.)
	AG	Xiong, Y. et al., "p21 is a universal inhibitor of cyclin kinases", <i>Nature</i> , Vol. 366, pp. 701-704 (1993).
	AH	Kaelin Jr., W. et al., "Identification of Cellular Proteins That Can Interact Specifically with the T/E1A-Binding Region of the Retinoblastoma Gene Product", <i>Cell</i> , Vol. 64, pp. 521-532 (1991).
	AI	Rigaut, G. et al., "A generic protein purification method for protein complex characterization and proteome exploration", <i>Nature Biotechnology</i> , Vol. 17, pp. 1030 to 1032 (1999).
	AJ	Fields, S. et al., "A novel genetic system to detect protein-protein interactions", <i>Nature</i> , Vol. 340, pp. 245-246 (1989).
ABS only	AK	Miyamoto-Sato, E., et al., "Construction of virus-type molecules in evolutionary molecular engineering", <i>Viva Origino</i> , Vol. 25, p. 35 (1997). (Partial English Translation.)
	AL	Doi, N. et al., "STABLE: protein-DNA fusion system for screening of combinatorial protein libraries <i>in vitro</i> ", <i>FEBS Letters</i> , Vol. 457, pp. 227-230 (1999).
	AM	Smith, G., "Filamentous Fusion Phage: Novel Expression Vectors that Display Cloned Antigens on the Virion Surface", <i>Science</i> , Vol. 228, No. 4705, pp. 1315-1317 (1985).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include cop. this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MKJ/

Sheet 2 of 2

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: July 27, 2006

ATTY DOCKET NO.  
2006\_0750ASERIAL NO.  
10/579,802APPLICANT  
Etsuko MIYAMOTO et al.FILING DATE  
May 18, 2006

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	BJ	95/11922 A1	05/1995	WO				
	BK							
	BL							
	BM							
	BN							

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	BO	Mattheakis, L. et al., "An <i>in vitro</i> polysome display system for identifying ligands from very large peptide libraries", <i>Proc. Natl. Acad. Sci.</i> , Vol. 91, pp. 9022 to 9026 (1994).
	BP	Bohmann, D. et al., "Human Proto-Oncogene c-jun Encodes a DNA Binding Protein with Structural and Functional Properties of Transcription Factor AP-1" <i>Science</i> , Vol. 238, No. 4832, pp. 1386-1392 (1987).
	BQ	Hilberg, F. et al., "c-Jun is essential for normal mouse development and hepatogenesis", <i>Nature</i> , Vol. 365, pp. 179-181 (1993).

EXAMINER

/Michele K. Jolke/

DATE CONSIDERED

10/10/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include cop. this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MKJ/